Truist raised the firm’s price target on Edwards Lifesciences (EW) to $78 from $70 and keeps a Hold rating on the shares. The company’s Investor Day presentation served as a clearing event, with FY25 outlook bracketing consensus, but while the firm’s price target increase reflects a forward roll of estimates to FY26, it also prefers to have more conviction in estimate upside and a stronger revenue acceleration trajectory, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $82 from $75 at BofA
- Edwards Lifesciences price target raised to $75 from $70 at TD Cowen
- Edwards Lifesciences price target raised to $68 from $63 at Canaccord
- Early notable gainers among liquid option names on December 4th
- Edwards Lifesciences sees FY25 adjusted EPS $2.40-$2.50, consensus $2.47